ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO711

Impact of Effective Treatment of Hyponatremia in Geriatric Patients

Session Information

  • Geriatric Nephrology
    October 27, 2018 | Location: Exhibit Hall, San Diego Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Geriatric Nephrology

  • 1100 Geriatric Nephrology

Authors

  • Burst, Volker Rolf, Department 2 of Internal Medicine, Renal Division; University of Cologne, Cologne, Germany
  • Grundmann, Franziska, University of Cologne, Cologne, Germany
  • Suárez, Victor, University Hospital of Cologne, Koeln, Germany
  • Todorova, Polina, University Hospital Cologne, Cologne, Germany
  • Brinkkoetter, Paul T., University Hospital Cologne, Cologne, Germany
Background

Hyponatremia is highly prevalent in old age and associated with increased morbidity and mortality. Until now it is not known whether effective treatment of frequently perceived asymptomatic hyponatremia in the geriatric population has an impact on patient outcome. Here, we investigate the effect of inpatient treatment of patients with hypotonic hyponatremia on neurocognitive and motor performance using a comprehensive geriatric assessment (CGA).

Methods

150 geriatric patients with serum [Na+] <130 mEq/L on admission and complete diagnostic datasets were enrolled. The results of the CGA on admission as well as the change of individual CGA tests until discharge were compared to a matched (sex, age, Barthel index of activities of daily living [ADL]) control group.

Results

Both groups were similar with respect to comorbidities and clinical characteristics. There were no differences in the individual assessments (ADL, Tinetti’s Mobility Assessment, Timed Up and Go-Test, Mini-Mental State Examination [MMSE], handgrip strength, Geriatric Depression Scale, Clock-drawing Test, and Esslinger Transfer Scale) at baseline (i.e. upon admission). A small but highly significant improvement as compared to the control group between baseline and time of discharge was observed with regard to ADL (mean(SD): 14.3(17.12)] vs. 9.84(14.67); P=0.002) and MMSE (mean(SD): 1.43(3.71) vs. 0.72(2.17); P=0.002) in the primary analysis group and this improvement was attributable to those patients in which serum [Na+] was increased by >5 mEq/L whereas no improvement was seen in those in which serum [Na+] was increased by only ≤5 mEq/L. However, regression analyses were not able to confirm a statistically significant association between effective [Na+] increase and CGA outcome within the primary analysis group. With respect to the subgroup of euvolemic hyponatremia, only changes of MMSE results were significantly different.

Conclusion

With the most robust changes observed with ADL and MMSE, the results of this prospective observational study suggest a true impact of treating hyponatremia on quality of life and neurocognitive function. However, the detected differences are small and further investigations are needed to prove their clinical relevance.

Funding

  • Commercial Support